The recently cloned human interleukin 13 (IL-13) is a novel cytokine expressed in activated T cells that has been shown to inhibit inflammatory cytokine production by lipopolysaccharideactivated monocytes. The protein encoded by the IL-13 cDNA is the human homologue of a mouse Th2-product called P600. Here, we show that IL-13 acts at different stages of the B cell maturation pathway: (a) it enhances the expression of CD23/FceRII and class II MHC antigens on resting B ceils; (b) it stimulates B cell proliferation in combination with anti-Ig and anti-CD40 antibodies; and (c) it induces IgE synthesis. Thus, the spectrum of the biological activities of IL-13 on B cells largely overlaps that previously ascribed to IL-4. The present observations suggest that IL-13 may be an important factor, in addition to IL-4, in the development of allergic diseases.
T
hl and Th2 T cell clones were first distinguished on the basis of their pattern of cytokine secretion (1, 2) . Thl cells produce IL-2, IFN'y, and lymphotoxin, whereas Th2 cells produce IL-4, IL-5, IL-6, and IL-10 (3). It is now clear that these two Th cell subsets also display distinct functional capabilities. Thl cells play an important role in cell-mediated immunity and are good mediators of delayed-type hypersensitivity and cytotoxic T cell responses (3, 4) . Conversely, Th2 cells are particularly effective in providing help for humoral responses (5) .
Human IL-13 has been recently cloned from a cDNA library established from activated PBMC (6) . IL-13 cDNA encodes a polypeptide of 12.4 kD with four potential N-glycosylation sites presenting 60% amino acid homology with a previously cloned mouse Th2 T cell product known as P600 (7, 8) . No biological activity has been reported so far for P600, but human IL-13 shares with two other Th2-derived cytokines (IL-4 and IL-10) the capacity to inhibit cytokine synthesis by activated monocytes (6, 9, 10) . Due to the specific expression of P600 by Th2 cells, the human counterpart of this molecule could be considered as a potential modulator of B cell responses. Here, we report on the effects of recombinant human IL-13 on the activation, proliferation, and differentiation of human B cells.
tion of 1/600, which provided the optimal costimulatory effect in proliferation assays. Formalinized particles of Staphylococcus aureus strain Cowan I (SAC) 1 were purchased as Pansorbin from Calbiochem-Behring Corporation (La JoUa, CA) and were used at a final concentration of 0.005% (vol/vol). Recombinant 11.-2 (3 x 106 U/rag) and purified recombinant IL-4 (2 x 107 U/mg) were purchased from Amgen Biologicals (Thousand Oaks, CA). Purified recombinant ILl0 was purchased from Immugenex (Los Angeles, CA) and was used at a final concentration of 100 ng/ml throughout the study. Recombinant IL-13 was purified from culture supernarants of stably transfected CHO cell lines, as described elsewhere (6) . The anti-CD40 mAb G28-5 (11) was kindly provided by Dr. E. A. Clark (University of Washington, Seattle, WA) and was used at a final concentration of 100 ng/ml. PE-conjugated anti-CD23 mAb and FITC-conjugated monoclonals directed against HLA-DR., DP, DQ antigens were purchased from Becton Dickinson & Co.
(Mountain View, CA). Culture supernatants of the OKT3 (CD3 mAb) and OKTll (CD2 mAb) hybridoma cell lines were used for depletion of T cells from tonsils. The blocking rabbit anti-human Ib4 polyclonal antibody was purchased from Genzyme (Cambridge, MA) and was used at the final concentration of 10/~g/ml. The corresponding negative control was a preimmune rabbit serum. The mouse Ltk-cell line D1B1 (12) , stably expressing the murine IgG Fc receptor (Fc3'RII) was kindly provided by Dr. C. Sautes (INSERM U. 255, Institut Curie, Paris, France).
B Cell Preparations. B cells were isolated from tonsils as previ-
Materials and Methods
Reagents and Cytokines. Rabbit anti-human Igs (heavy and light chains) coupled to polyacrylamide beads were purchased from BioRad Laboratories (Richmond, CA) and were used at a final dilu-ously described (13) , Briefly, after a rosetting step with sheep red blood cells, nonrosetting cells were further incubated with anti-CD2 and anti-CD3 mAbs before negative selection performed with magnetic beads coated with anti-mouse IgG (Dynabeads; Dynal, Oslo, Norway). The purity of the B cell populations obtained by this procedure was routinely superior to 98% as estimated by flow cytometry analysis using anti-CD19, -CD20, -CD2, -CD3, and -CD14 mAbs. slgD + and slgD-B cells were isolated as described previously (13) using a preparative magnetic cell separation system (MACS| Becton Dickinson & Co.). The purity of both B cell populations was routinely superior to 95%.
Leukemic B cells were obtained from a patient with hematologically diagnosed chronic lymphocytic leukemia. B cells were isolated from peripheral blood, according to the procedure described above, and contained more than 95% leukemic cells as estimated by the expression of the CD5 antigen, which is constitutively expressed on chronic lymphocytic leukemia B cells (B-CLL).
Cultures. All cultures were performed in RPMI 1640 supplemented with 10% selected heat-inactivated FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 #g/ml streptomycin, and 2% Hepes (all from Gibco Laboratories, Grand Island, NY). For CD23 and class II MHC antigen induction experiments, B cells (106/ml) were cultured for 48 h in the absence of stimulating agent, or in the presence of IL-4 or IL-13 used at 100 ng/ml. At the end of the culture period, cells were stained with PE-conjugated anti-CD23 or FITCconjugated anti-HLA-DR, DP, or DQ monoclonals and analyzed on a FACScan | using the Lysis software. (Becton Dickinson & Co.) Propidium iodide (2 #g/ml) was added to each sample (except when staining was performed with PE-conjugated antibodies) before flow cytometry analysis to gate out nonviable cells. For proliferation assays, B cells were seeded at 1.5 x 105 cells/well in 96-well microtiter trays in a final volume of 0.1 ml. Cytokines and polyclonal B cell activators (anti-Ig or anti-CD40 antibodies) were added at the onset of the culture. Each culture point was performed in triplicate. At the times specified in the text, DNA synthesis was determined by pulsing the cells with [3H]thymidine ([3HITdR) for the last 16 h of the culture period. For differentiation assays performed with polyclonal B cell activators (SAC and anti-CD40 mAb), B cells were seeded at 3 x 1@ cells per well in 96-well microtiter trays, in a final culture volume of 0.25 ml. When SAC was used as the stimulating agent, the addition of cytokines was made either at the onset of the culture (costimulation assay) or was delayed for 2 d (restimulation assay). For assays aimed at determining the influence of IL-13 on IgE synthesis, two distinct activation systems were used. In the first one, B cells were co-cultured with mitomycintreated (75 #g/ml, 45 rain, 370C) T cells activated by phytohemagglutinin-P (PHA; Difco Laboratories, Inc., Detroit, MI). In these experiments, 3 x 1@ T cells, purified from peripheral blood by filtration on nylon wool columns, were added together with cytokines and PHA (1/~g/ml) to 5 x 10 s B cells, in 24-well plates, in a final volume of 1 ml. In the second one, purified B cells were activated by the anti-CD40 mAb G28-5 presented by the D1B1 cell line, stably expressing the murine FcTRII. In these experiments, 5 x 10 s B cells were co-cultured in 24-well plates with 2 x 105 irradiated (7,000 rad) DIB1 cells and the G28-5 mAb (100 ng/ml) in the presence of IL4 (200 ng/ml) or IL-13 (100 ng/ml), with or without addition of anti-IL4 or control antisera (10 #g/ml). Each culture point was performed in six replicates (T/B cell co-cultures) or in quadruplicates (co-cultures with DIB1 cells). For determination ofimmunoglobulin production, culture supernatants were harvested at day 10 and IgM, IgG, IgA, and IgE levels were measured in standard ELISAs (14, 15) .
Results

IL-13 Enhances Expression of CD23 and Class II MHC Antigens on B Cells.
To examine the capacity of IL-13 to exert an influence on the early B cell activation steps, both tonsillar B cells and leukemic B cells from a B-CLL patient were assessed for CD23 expression after a 48-h culture period in the presence of 100 ng/ml purified recombinant IL-13 or IL-4. The results from one representative experiment are illustrated by Fig. 1 . As described earlier (16, 17) , CD23 was constitutively expressed on the leukemic clone ( Fig. 1 E) , whereas it was only distributed on a subset of normal B cells (Fig.  1 A) . In agreement with previously published reports (17) , normal and leukemic B cells (Fig. 1, B and F, respectively) almost totally lost the expression of CD23, in the absence of stimulant. Both IL-13 ( Fig. 1, C In contrast with IL-4, IL-13 totally failed to enhance CD23 expression on the Burkitt lymphoma cell line Jijoye (data not shown). As illustrated by Fig. 2 , IL-13 was also able to significantly increase expression of the HLA-DR, DP, and DQ antigens on B-CLL cells. At optimal concentrations of both cytokines, the signal provided by IL-13 for enhancement of class II MHC antigens was of similar amplitude to that provided by IL-4 (data not shown), and up to sixfold increases in MFI were observed for HLA-DP antigens in response to IL-13.
IL-13 Stimulates Growth of Activated B Cells.
Purified recombinant IL-13 and IL-4 were next compared for their capacity to stimulate DNA synthesis from human tonsillar B cells activated either through cross-linking of surface Igs using immobilized anti-Ig antibodies or through ligation of CD40 antigens using the anti-CD40 mAb G28-5. As shown in Fig. 3 , IL-13 enhanced [3H]TdR incorporation of activated human B lymphocytes, in a dose-dependent fashion, in both culture systems, a plateau being reached at 50 ng/ml. As observed for CD23 induction, the half-maximal effect of IL-13 on B cell proliferation was obtained for a concentration of ~3 ng/ml. On average, at optimal concentration of both cytokines, the levels of cytokine concentration (ng/ml) Figure 3 . Titration of the growth-promoting activity of II.-13 on B cells activated through slgs or CD40. 1.5 x 10 s B cells were cultured with serial dilutions of purified recombinant IL-13 or purified recombinant IL-4, in combination with immobilized anti-Ig antibodies (1/600 dilution) or with the anti-CD40 mAb G28-5 (100 ng/ml).
[3H]TdR incorporation levels were assessed at day 3, after a 16-h pulse. The mean +_ SD rates of incorporation from triplicate wells of a typical experiment are shown. The figure is representative of three separate experiments.
shown). To examine whether IL-13 could modulate the growth-promoting effect of other B cell stimulatory cytokines, anti-Ig or anti-CD40-activated B cells were cultured with optimal concentrations of IL-2 (20 U/ml), IL-4 (200 ng/ml), or IL-10 (100 ng/ml) in the presence or absence of an optimal concentration of IL-13 (100 ng/ml). As indicated by the data summarized in Table 1 , IL-2 and IL-10, but not IL-4, were able to cooperate with IL-13 to induce proliferation of activated B cells. As expected from previous results (18), IL-2 failed to stimulate DNA synthesis from anti-CD40-activated B cells, whereas IL-10 was virtually inactive on anti-Ig-activated B cells. Accordingly, enhancement by IL-13 of the growth-promoting effects of IL-2 and IL-10, was observed in the anti-Ig and anti-CD40 activation systems, respectively. As demonstrated by kinetics studies (Fig. 4) As a control, the influence of IL-2 and anti-Ig antibodies on the growth response of both populations was also examined. As shown in Fig. 5 , slgD + B cells displayed an enhanced responsiveness to the growth stimulatory effect of IL-13, when compared with slgD-B cells, in both the antiqg and anti-CD40 activation systems. The levels of DNA synthesis induced by IL-13 in the former population were, on average, two to five times superior to those induced in the latter. In contrast, the proliferative response of slgD-B cells to the combination of IL-2 and immobilized anti-Ig antibodies was markedly higher than that of slgD + B cells, at all time points. This observation therefore rules out the possibility of an impaired responsiveness of slgD-/3 cells to mitogenic stimuli. Taken together, these findings indicate that IL-13 is a B cell growth-factor whose preferential cellular target is virgin slgD + B cells.
IL-13 Induces IgE Synthesis.
We next examined the activity of IL-13 on B cell differentiation. IL-13 was first compared with IL-2 for its capacity to induce polyclonal Ig secretion from activated B cells, in four distinct assay systems: (a) coculture with SAC; (b) co-cuhure with the anti-CD40 mAb G28-5; (c) co-culture with SAC and anti-CD40; (d) restimulation of B cells preactivated with SAC for 2 d. The latter culture condition was included in our study in order to avoid underestimation of the Ig-inducing activity of IL-13 due to its presence during the initial activation with SAC. Indeed, the development of the stimulatory effect of IL-4 on B cell differentiation had been shown to be prevented when SAC and IL-4 were added simultaneously on B cells (19) . As shown in Table 2 , IL-13 failed to stimulate IgM, IgG, and IgA synthesis, whatever the mode of B cell activation used. However, a low but reproducible IgE response was observed when B cells were co-cultured with IL-13 and soluble anti-CD40 antibodies. In spite of its capacity to enhance the proliferative response induced by IL-2 and IL-10, IL-13 did not affect the IgM, [gG, and IgA synthesis elicited by these two cytokines in the SAC restimulation assay (Fig. 6 ) or in the three other culture systems described above (data not shown). IL-13 also Purified B ceils were seeded at 3 x 10 s cells/well and activated by SAC (0.005%, vol/vol), by the anti-CD40 mAb G28-5 (100 ng/ml) or by the combination of SAC and anti-CD40 in the presence or absence of optimal concentrations of IL-13 (100 ng/ml) or IL-2 (10 U/ml). When SAC was used as the stimulating agent, cytokines were either added together with SAC at the onset of the culture (costimulation assay) or 2 d after establishment of the culture (restimulation assay). Supernatants were harvested at day 10 and Ig levels were determined by ELISA. Results are means of quadruplicate determinations. SD never exceeded 10% of the mean values. IgM, IgG, and IgA levels are expressed in/xg/ml, IgE levels are expressed in pg/ml. This table is representative of four separate experiments. (100 ng/ml), and ILl0 (100 ng/ml) were added alone or in the presence of Ib13 (100 ng/ml) on the second day of the culture. Ig levels were tested in 10-d culture supernatants by specific ELISAs. Results are expressed in /zg/ml and correspond to the mean _+ SD values calculated on eight culture replicates, m, -IL13; D, +IL-13. failed to modulate the IL-4-mediated secretion of these isotypes. Since signals provided by activated T cells have been described to be instrumental for induction of IgE synthesis in response to IL-4 (20, 21), IL-13 was first tested for its IgEinducing capacity in cultures in which B cells were activated by mitomycin-treated T cells, in the presence of PHA (1 /zg/ml). Because activated T cells have been shown to induce B cells for DNA synthesis and Ig secretion in a class II unrestricted and nonantigen-specific fashion (22) , T cells used for T/B cell co-cultures were isolated from peripheral blood, whereas B cells were purified from tonsils. The T/B cell ratio in these experiments was 6/1. As shown in Table 3 , IL-13 did not significantly enhance the production of IgM, IgG, and IgA but markedly increased the IgE synthesis induced by activated T cells. To rule out the possibility that part or all of the IgE-inducing activity of IL-13 could be mediated through the endogenous release of IL-4, IL-13 was also tested for its capacity to induce IgE synthesis in a culture system devoid of potential IL-4-producing cells. Regarding that IL-4 can efficiently stimulate B cells for IgE secretion when they are activated by anti-CD40 antibodies presented by a mouse fibroblastic cell line transfected with the human IgG Fc receptor (23), we decided to assess the IgE-stimulatory effect of IL-13 in a similar experimental model. For this purpose, B cells were co-cultured with the anti-CD40 mAb G28-5, presented by the D1B1 cell line stably expressing the murine Fc3,RII, and IL-4 or IL-13, in the presence or absence of a rabbit anti-human IL-4 polyclonal antibody. As shown in Table 4 , IL-4 and IL-13, both used at optimal concentrations, induced equivalent levels of IgE synthesis from B cells activated by immobilized anti-CD40 antibodies. IL-13 failed to stimulate any IgM or IgA production in that culture system, but marginal enhancements (two times the background levels) of IgG secretion were observed (data not shown). Neutralizing polyclonal anti-IL-4 antibodies, but not the preimmune rabbit serum, completely blocked the IgE-inducing activity of IL-4. In contrast, the anti-IL-4-neutralizing antiserum did not antagonize the IgE-stimulatory effect of IL-13. Taken together these results indicate that IL-13 stimulates IgE secretion in an IL-4-independent fashion.
Discussion
In the present report, we have demonstrated that human IL-13 is susceptible to act on three distinct stages of the B cell maturation process: (a) during the early activation phase, by enhancing expression of CD23 and of class II MHC antigens on resting B cells; (b) during the proliferation phase, by stimulating growth of activated B cells; (c) during the differentiation phase, by inducing IgE synthesis. Thus, the spectrum of biological activities of IL-13 on human B cells presents striking similarities with that previously ascribed to IL-4 (24), although the IL-13-mediated responses were generally of lower amplitude than those elicited by IL-4. For example, the levels of CD23 expressed on IL-13-stimulated B cells, after 48 h of culture, were approximately equivalent to those found on freshly isolated B cells. In contrast, IL-4 not only induced higher levels of CD23 expression but also recruited a larger proportion of tonsillar B cells to become CD23-positive. In view of the fact that CD23 rapidly disappears from the B cell membrane in the absence of stimulant Purified tonsillar B cells (5 x 10S/well) were co-cultured for 10 d with mitomycin-treated peripheral blood T cells (3 x 106/well) and PHA (1 /xg/ml) in the absence or in the presence of IL-4 (100 ng/ml) or IL-13 (100 ng/ml). Each culture point was performed in six replicates in 24-well plates under a final culture volume of 1.0 ml. Supernatants from the culture replicates were pooled and Ig levels were determined by ELISA. Results are expressed as means • SD of quadruplicate ELISA determinations. IgM, IgG, and IgA levels are expressed in/~g/ml, IgE levels are expressed in ng/ml. (17), it can not be excluded that IL-13 acts by stabilizing the CD23 molecule on the cell surface (for example by preventing the proteolytic cleavage or shedding of its soluble form) rather than by activating the CD23 gene.
As observed for CD23 induction, the growth-stimulatory effect of IL-13 on B cells activated either through cross-linking of slgs or ligation of CD40 was less pronounced than that of IL-4. Examination of the B cell proliferative response to IL-13 used in combination with other B cell-stimulatory cytokines revealed one point of discrepancy between IL-4 and IL-13. Indeed, although IL-4 and IL-13 shared the capacity to enhance the growth-response induced by IL-10 (25), IL-13 potentiated the DNA synthesis elicited by IL-2, whereas there is published evidence that IL-4 antagonizes the human B cell Purified tonsillar B cells (5 x 10S/well) were activated by the anti-CD40 mAb G28-5 (100 ng/ml) presented by the irradiated fibroblast cell line DIB1 stably expressing the murine Fc~/RII (2 x 10S/well). Anti-CD40-activated B cells were cultured with purified recombinant IL-4 (100 U/ml) or IL-13 (100 ng/ml) in the presence or absence of: (a) a rabbit anti-human IL-4 polyclonal antibody (10/~g/ml); (b) a control rabbit anti-serum (10/~g/ml). Each culture point was performed in quadruplicates in 24-well plates. Supernatants from the culture replicates harvested on day 10 were pooled and IgE concentrations were measured by ELISA. Results are expressed as means _+ SD of quadruplicate ELISA determinations. IgE levels are expressed in ng/ml. *Med, Medium.
responses to this cytokine (26, 27) . We suspect that the positive interplay between IL-2 and IL-13 on B cell proliferation could relate to the fact that the two molecules have distinct cellular targets. IL-13 predominantly induced growth of slgD + B cells, whereas, in accordance with a previous published report (28), IL-2 had a preferential impact on the slgD-subset which is enriched for GC-derived B cells. This finding is consistent with the hypothesis that a larger B cell population is recruited to proliferate when IL-2 and IL-13 are combined, than when each cytokine is used alone. Additionally, the enhanced responsiveness of virgin slgD + B cells to IL-13 raises the possibility that this cytokine could be involved in the establishment of the primary humoral response rather than in the development of the secondary immune response. Despite the fact that IL-13 behaved as a B cell growthfactor, it was virtually unable to induce IgM, IgG, and IgA synthesis from activated B cells in different assay systems, thus implying that IL-13 does not play a major role in the regulation of the production of these Ig isotypes. However, IL-13 selectively stimulated IgE secretion from B cells co-cultured with activated T cells or with an anti-CD40 mAb presented by a fibroblastic cell line expressing the murine Fc~/RII. The observation that neutralizing anti-IL-4 antibodies failed to antagonize the IgE-stimulatory effect of IL-13, in a T cell-free culture system demonstrates that IL-13 operates through an IL-4-independent mechanism. Since the biological effects of IL-13 are preferentially directed at slgD + B cells it is likely that the IgE-inducing activity of IL-13 results from isotype switching rather than from differentiation of IgE-committed precursors.
Based on the observation that IL-4 and IL-13 have a highly overlapping set of biological activities on human B cells, it is tempting to speculate that these two cytokines, despite limited protein sequence homology, could share receptor signaling pathways. Experimental evidence has been provided that this is the case for other cytokines such as IL-5, IL-3, and GM-CSF which share a common receptor suhunit responsible for signal transduction (29) . Until recently, the IL-4 receptor was believed to consist of a single chain binding IL-4 with high affinity and capable of transmitting a growth signal when transfected in various cell lines (24, 29) . However, two lines of evidence now support the existence of two IL-4 receptors of different affinities, possibly coupled to separate signal transduction pathways. First, Rigley et al., (30) have shown that the IL-4-mediated enhancements of sIgM and CD23 expression on human B cells are regulated independently through distinct second messenger cascades. Second, an additional IL-4 binding protein of low affinity has recently been identified on human pre-B cells (31) . Thus, the possibility exists of a multisubunit IL-4 receptor including potential IL-13 signal transducing molecules. It can not be excluded that the IL-13 receptor may also be coupled to a unique signaling pathway, as suggested by the observation that IL-4 and IL-13 display opposite effects on the IL-2-mediated proliferation of activated B cells.
Although IL-13 would appear to contribute an additional redundancy in the cytokine regulation of the B cell maturation process it may be unique in its capacity to preferentially induce growth of virgin slgD + B cells. It does not significantly affect the production of the IgM, IgG, and IgA isotypes but stimulates IgE synthesis and as such might contribute to the development of allergic diseases. In keeping with this, although IL-4 has been implicated by gene-deletion experiments (32, 33) as the major, if not the unique switch factor for IgE in the mouse, the existence of an additional IgE-inducing activity, produced by T cells from atopic patients, has been recently demonstrated (34) . This observation raises the possibility that an IL-4-independent mechanism of IgE regulation, possibly mediated by IL-13 might operate in atopic individuals.
